MJP Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.43M Buy
3,732
+382
+11% +$387K 0.42% 35
2025
Q4
$3.6M Buy
3,350
+260
+8% +$249K 0.45% 31
2025
Q3
$2.36M Sell
3,090
-391
-11% -$291K 0.31% 34
2025
Q2
$2.71M Sell
3,481
-90
-3% -$69.9K 0.4% 29
2025
Q1
$2.95M Buy
3,571
+74
+2% +$61.6K 0.53% 30
2024
Q4
$2.7M Buy
3,497
+217
+7% +$180K 0.49% 31
2024
Q3
$2.91M Buy
3,280
+276
+9% +$248K 0.55% 29
2024
Q2
$2.72M Buy
3,004
+10
+0.3% +$8K 0.57% 27
2024
Q1
$2.33M Buy
2,994
+604
+25% +$430K 0.51% 28
2023
Q4
$1.39M Sell
2,390
-8
-0.3% -$4.67K 0.37% 28
2023
Q3
$1.29M Buy
2,398
+183
+8% +$94.3K 0.37% 27
2023
Q2
$1.04M Buy
2,215
+602
+37% +$252K 0.34% 36
2023
Q1
$554K Buy
1,613
+41
+3% +$13.8K 0.17% 66
2022
Q4
$575K Buy
1,572
+503
+47% +$178K 0.17% 63
2022
Q3
$346K Buy
1,069
+45
+4% +$14.3K 0.1% 85
2022
Q2
$332K Buy
1,024
+167
+19% +$50.1K 0.09% 89
2022
Q1
$245K Sell
857
-147
-15% -$37.8K 0.06% 130
2021
Q4
$273K Buy
1,004
+117
+13% +$29.7K 0.08% 118
2021
Q3
$205K Buy
887
+17
+2% +$4.2K 0.07% 134
2021
Q2
$200K Buy
+870
New +$175K 0.07% 135

Other funds holding LLY

MJP Associates's LLY Position: Q1 2026 in Review

MJP Associates increased its Eli Lilly (LLY) stake by 11% in Q1 2026, buying an estimated $387K and bringing the position to 3,732 shares worth $3.43M. The position accounts for 0.42% of the portfolio, ranked #35.

MJP Associates first reported a position in LLY in Q2 2021 and has held it in 20 quarters since. The position peaked at $3.6M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • MJP Associates held 3,732 shares of Eli Lilly worth $3.43M as of Q1 2026.
  • MJP Associates bought 382 Eli Lilly shares in Q1 2026, an estimated $387K.
  • Eli Lilly made up 0.42% of MJP Associates's portfolio in Q1 2026, its #35 holding.
  • MJP Associates first reported a position in Eli Lilly in Q2 2021 and has held it in 20 quarters since.
  • MJP Associates's Eli Lilly position peaked at $3.6M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on MJP Associates's 13F filing for Q1 2026, filed 5 May 2026.